Mumbai (Udaipur Kiran News): Shares of Biocon Ltd rose over 1.6% in Wednesday’s trading session after its subsidiary, Biocon Biologics, signed a settlement and license agreement with Amgen Inc. paving the way for the commercial launch of its biosimilar drugs Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the United States.

The stock was trading at ₹346.35, up ₹5.50 or 1.61%, compared to its previous close of ₹340.85 on the BSE. The scrip opened at ₹340.20 and touched an intraday high of ₹348.15 and a low of ₹340.20. A total of 30,779 shares have been traded so far.

The BSE Group ‘A’ stock has a 52-week high of ₹405.90 (July 18, 2025) and a 52-week low of ₹290.80 (March 3, 2025). In the last week, it traded between ₹367.95 and ₹337.20. The company’s market capitalization stands at ₹46,305.74 crore.

Promoter holding in the company is 54.45%, while institutional investors own 28.86% and non-institutional investors hold 16.68%.

🔹 Key Development

Biocon Biologics has entered into a settlement and license agreement with Amgen Inc., resolving the pending patent litigation in the U.S. District Court for the District of New Jersey. The agreement allows Biocon Biologics to commercially launch Bosaya and Aukelso in the U.S. from October 1, 2025.

Both Bosaya (60 mg/mL injection) and Aukelso (120 mg/1.7 mL injection) are biosimilars to Amgen’s Prolia and Xgeva, respectively. These products are used in the treatment of osteoporosis and cancer-related bone conditions.

The development marks a major milestone for Biocon Biologics, which is a fully integrated global biosimilars company.

Biocon Ltd is India’s largest and Asia’s leading biotechnology firm, focused on biopharmaceuticals and research services. It offers affordable treatment solutions for chronic diseases to patients worldwide.